Novartis (Sweden)

Recent papers from Novartis (Sweden)

1. Mobilizing core and country-tailored implementation strategies to accelerate Lipoprotein(a) testing across Europe: findings from the Lp(a)CCELERATE contextual analysisEuropean Heart Journal · 2026
2. Characteristics and Outcomes of NATALEE- and monarchE-Eligible Early Breast Cancer in Finland: A Regional Real-world Cohort StudyThe Oncologist · 2026
3. Lp(a)ccelerate: Contextual Analysis to Integrate Lp(a) Testing in Routine Cardiovascular Care Using Implementation ScienceAtherosclerosis · 2026
4. Elevated lipoprotein(a) is associated with increased risk for MACE in patients with premature and recurrent atherosclerotic cardiovascular disease: a large real-world cohort studyBMC Cardiovascular Disorders · 2026
5. 687P Recurrence risk and overall survival in stage II ER+/HER2- early breast cancer patients: A population-based registry study in SwedenESMO Open · 2026
6. Major cardiovascular events in first-degree relatives to individuals with elevated plasma lipoprotein(a) a registry-based cohort studyEuropean Heart Journal · 2025
7. Prevalence of elevated lipoprotein(a) in premature ASCVD patients and its association with major adverse cardiovascular events: analysis of a large US electronic health record databaseEuropean Heart Journal · 2025
8. Association of elevated lipoprotein(a) with future major adverse cardiovascular events in recurrent ASCVD patients: analysis of a large US electronic health record databaseEuropean Heart Journal · 2025
9. Exploring young women's experiences throughout the journey of hormone-sensitive breast cancer: A qualitative secondary analysisEuropean Journal of Oncology Nursing · 2025
10. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort studyEuropean Heart Journal · 2025
11. Status and timing of angiotensin receptor–neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure RegistryEuropean Journal of Heart Failure · 2024
12. Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future researchEuropean Journal of Preventive Cardiology · 2024
13. Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK BiobankENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2023
14. Current treatment landscape of HR+/HER2− advanced breast cancer in the Nordics: a modified Delphi studyActa Oncologica · 2023
15. Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort studyActa Oncologica · 2023
16. A Description of the Yield of Genetic Reinvestigation in Patients with Inherited Retinal Dystrophies and Previous Inconclusive Genetic TestingGenes · 2023
17. Economic burden of sickle cell disease in Sweden: a population-based national register study with 13 years follow upFrontiers in Hematology · 2023
18. Characterization of clinicopathological features, treatment practices, and outcomes among Finnish advanced breast cancer patients in real-life clinical practiceJournal of Cancer Research and Clinical Oncology · 2023
19. Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United StatesJournal of Managed Care & Specialty Pharmacy · 2023
20. Prevalence and Prognostic Impact of Left Ventricular Systolic Dysfunction or Pulmonary Congestion After Acute Myocardial InfarctionESC Heart Failure · 2023